Award
Award #75F40126D00023
IDIQ Award for Pharmaceutical Products to We Pharma, Inc.
Buyer
Food and Drug Administration
Award Amount
$4,000,000.00
Ceiling
$4,000,000.00
Awarded
September 15, 2026
Period of Performance
Sep 15, 2026 – Sep 14, 2031
Identifier
75F40126D00023
NAICS
325412
This contract is an Indefinite Delivery Indefinite Quantity (IDIQ) agreement awarded to We Pharma, Inc., a company specializing in pharmaceutical supply and development. The contract covers the procurement of a wide range of pharmaceutical products used in research studies conducted by the Center for Drug Evaluation and Research (CDER). These products include both brand name and generic pharmaceuticals, encompassing small molecule and peptide therapeutics, drug-device combination products, and contrast agents. The significance of this contract lies in its support of essential medical research, potentially advancing drug development and regulatory science. The scope involves delivering a diverse portfolio of pharmaceutical items necessary for CDER's ongoing research efforts. This award was likely the result of a competitive bidding process, reflecting the complexity and importance of the pharmaceutical supplies needed. Scheduled as a multi-year contract spanning from late 2026 to late 2031, it ensures sustained support for critical research activities over several years. While specific subcontractors and prior related contracts were not detailed, the award represents a significant investment in pharmaceutical research resources.
Description
IDIQ FOR PHARMACEUTICAL PRODUCTS FOR CDER RESEARCH STUDIES. INCLUDES BRAND NAME AND/OR GENERIC PHARMACEUTICALS TO INCLUDE SMALL MOLECULE AND PEPTIDE THERAPEUTICS, DRUG-DEVICE COMBINATION PRODUCTS, AND CONTRAST AGENTS. EO 14398